0
Détail de l'auteur
Auteur E. Slump |
Documents disponibles écrits par cet auteur (2)
Ajouter le résultat dans votre panier Affiner la recherche
Monitoring latent tuberculosis infection diagnosis and management in the Netherlands / C.G.M. Erkens (2016)
Titre : Monitoring latent tuberculosis infection diagnosis and management in the Netherlands Type de document : document électronique Auteurs : C.G.M. Erkens, Auteur ; E. Slump, Auteur ; Maurits Verhagen, Auteur ; H.J. Schimmel, Auteur ; Gerard de Vries, Auteur ; Frank Cobelens, Auteur ; Susan van den Hof, Auteur Editeur : European Respiratory Society (ERS) Année de publication : 2016 Collection : European Respiratory Journal num. vol.47 nr 4 Importance : p.1492-1501 Langues : Anglais (eng) Catégories : [DIVERS] géographie:Europe:Europe occidentale:Pays-Bas
[TUBER] diagnostic
[TUBER] traitement
[TUBER] type de tuberculose:infection tuberculeuse latenteIndex. décimale : TU 2. Type de tuberculose et pathogies similaires Résumé : Targeted diagnosis and treatment of latent tuberculosis (TB) infection (LTBI) among persons with a high risk of exposure to TB or of developing TB when infected has been performed and monitored routinely in the Netherlands since 1993. We describe trends in target groups, diagnostic methods and treatment regimens, and explore determinants for treatment initiation, treatment completion and adverse events.
In total, 37 729 persons were registered with LTBI from 1993 to 2013, of whom 28 931 (77%) started preventive treatment; 82% of those completed preventive treatment and 8% stopped preventive treatment due to adverse events. Two-thirds of the notified cases were detected through contact investigation.
Increasing numbers of persons with immunosuppressive disorders, elderly persons and foreign-born persons were notified in recent years, due to policy changes and the introduction of the interferon-γ release assay. Children (96%) and the immunosuppressed (95%) were more likely to start preventive treatment. Children (93%) were also more likely to complete preventive treatment, as were persons treated with rifampicin or rifampicin/isoniazid regimens (91% and 92%, respectively). The latter groups were also 40% less likely to stop preventive treatment due to adverse events.
Under these operational conditions, the estimated risk reduction on incident TB in the target population for LTBI management is 40–60%.En ligne : https://doi.org/10.1183/13993003.01397-2015 Format de la ressource électronique : Article en ligne Permalink : https://biblio.fares.be/opac_css/index.php?lvl=notice_display&id=10153 Aucun avis, veuillez vous identifier pour ajouter le vôtre !
Titre : Tuberculose in Nederland 2022 : Surveillancerapport Type de document : document électronique Auteurs : E. Slump, Auteur ; R. Anthony, Auteur ; M.P. Kamst-van Agterveld, Auteur ; A.C. Mulder, Auteur ; H.J. Schimmel, Auteur ; E. Stempher, Auteur ; Gerard de Vries, Auteur Editeur : Bilthoven [Nederland] : Rijksinstituut voor Volksgezondheid en Milieu = National Institute for Public Health and the Environment Année de publication : 2023 Collection : RIVM Report num. 0406 Importance : 76 p. Langues : Néerlandais (nla) Anglais (eng) Langues originales : Néerlandais (nla) Catégories : [DIVERS] géographie:Europe:Europe occidentale:Pays-Bas
[DIVERS] type de document:rapport
[TUBER] étude:épidémiologie
[TUBER] type de tuberculose:tuberculose-maladieIndex. décimale : TU 4.6. Pays développés (Amérique du Nord, Europe, Océanie) Résumé : In 2022, 635 tuberculosis (TB) patients were notified in the Netherlands. This is six per cent fewer than in 2021, when there were 673 patients. This decline is consistent with the downward trend in TB cases in the Netherlands over the past 20 years.
In 2020 patient numbers fell more sharply than in the years prior. Between March 2020 and May 2022, coronavirus measures including social distancing and less contact with others were in effect in the Netherlands. This most likely mitigated the spread of the TB bacterium. Another mitigating factor was the decline in the number of immigrants and asylum seekers who came to the Netherlands in 2020 as a result of global travel restrictions.
TB is more prevalent among those not born in the Netherlands. In 2022, this was the case for four out of every five patients. Most patients were born in Eritrea (70), followed by Morocco (59) and Somalia (36). TB is widespread in Africa and Asia.
TB is an infectious and potentially contagious disease caused by a bacterium. Of the 635 patients who had TB in 2022, more than 60 per cent had pulmonary TB and the remaining patients had extrapulmonary TB. A quarter of all patients had the most contagious type (open TB).
People who have become infected with the bacterium but have not developed TB (yet) are said to have contracted a TB infection. Early detection of TB infections makes it possible for these people to be treated before they become ill. This, in turn, prevents the TB from spreading to other people. In addition to the 635 people who became ill in 2022, almost 1,200 people were reported to have contracted a TB infection. More than a quarter of these people was traced using source and contact tracing among those known to have been in close contact with a TB patient. A third were traced by testing new arrivals from countries were TB is widespread.
RIVM reports the number of TB cases and TB infections each year in order to monitor the effect of measures to reduce the incidence of TB in the Netherlands. These measures are described in the National Tuberculosis Control Plan 2021–2025.En ligne : https://www.rivm.nl/publicaties/tuberculose-in-nederland-2022 Format de la ressource électronique : Page de l'éditeur Permalink : https://biblio.fares.be/opac_css/index.php?lvl=notice_display&id=10125 Aucun avis, veuillez vous identifier pour ajouter le vôtre !